{{ currentBoardShortName }}
  • Markets
  • Indices
  • FX
  • Energy
  • Metals
Markets
As of: {{timeStamp.date}}
{{timeStamp.time}}

Markets

{{ currentBoardShortName }}
  • Markets
  • Indices
  • FX
  • Energy
  • Metals
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}

Commodities Videos

VIDEO SIGN OUT

{{ currentStream.Name }}

{{ currentStream.Desc }}

Related Video

Continuous Play:
ON OFF

The information you requested is not available at this time, please check back again soon.

From aluminum to zinc and everything in between, join BNN for the latest insight into the hot world of commodities and the companies that produce them, including interviews with mineral and mining entrepreneurs from Canada and around the globe. Whether it's a gold play in the Andes or a hot offshore oil prospect, BNN has you covered on commodities. 

 

Email: commodities@bnn.ca

Dec 1

'Don’t do it': Marijuana stocks 'very risky' for investors, money manager says

VIDEO SIGN OUT

Security Not Found

The stock symbol {{StockChart.Ric}} does not exist

See Full Stock Page »

Canopy Growth Corp., Canada’s largest publicly-traded marijuana company, announced Thursday it will acquire rival pot producer Mettrum Health Corp. in a $430-million stock deal – but the news isn’t enough to sway one Toronto-based money manager, who says investing in the marijuana sector is “very risky.”

“These are not the types of investments that I would make for my clients,” Barry Schwartz, chief investment officer at Baskin Wealth Management, said on BNN Thursday. “These are not profitable companies. They don’t pay dividends. I don’t know if this is a moat business – I think anybody can grow marijuana.”

In its earnings report last month, Canopy (CGC.TO) said second-quarter revenue rose to $8.5 million -- a 245 per cent increase over the same period last year. Around the same time, a number of Canadian marijuana stocks experienced wild swings and were later halted after the election of Donald Trump as U.S. president and anticipation for the Liberal government’s legalization of recreational marijuana.

Mettrum CEO: Why I sold Canada's No. 2 weed grower

Michael Haines , CEO and director at cannabis company Mettrum Health, tells us why he agreed to a $400-million-plus takeover by Canopy Growth.

The country’s publicly-traded marijuana companies that saw spikes in trading included Canopy, Aurora Cannabis Inc. (ACB.V), Mettrum (MT.V), Aphria Inc. (APH.V), OrganiGram Holdings Inc. (OGI.V), and Supreme Pharmaceuticals Inc. (SL.CD).

While remaining opposed to the idea of investing in pot stocks, Schwartz acknowledged that marijuana companies could have some advantages if they are licensed and are working with the government.

“But at the end of the day, it’s very risky in our opinion. It’s not the type of investment we’d ever make,” he added, saying “don’t do it” when asked what he would tell investors determined to buy into the sector.

“Everybody and their brother is going public as a marijuana company,” Schwartz said. “We are going to see a lot of IPOs in the next few years. There’s going to be tons of competition – not everyone is going to survive.”